Recombinant Mycobacterium Bovis Bacillus Calmette-Guérin Secreting Merozoite Surface Protein 1 (MSP1) Induces Protection Against Rodent Malaria Parasite Infection Depending on MSP1-stimulated Interferon Gamma and Parasite-specific Antibodies

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1998 Sep 9

PMID 9730886

Citations 26

Authors

S Matsumoto

H Yukitake

H Kanbara

T Yamada

Affiliations

Soon will be listed here.

Abstract

The merozoite surface protein 1 (MSP1) has emerged as a leading malaria vaccine candidate at the erythrocytic stage. Recombinant bacillus Calmette-Guérin (rBCG), which expressed a COOH-terminal 15-kD fragment of MSP1 of Plasmodium yoelii (MSP1-15) as a fusion protein with a secretory protein of Mycobacterium kansasii, was constructed. Immunization of mice with this rBCG induced a higher degree of protection against blood-stage parasite infection than with recombinant MSP1-15 in the RIBI adjuvant (RIBI ImmunoChem Research, Inc., Hamilton, MT) or incomplete Freund's adjuvant systems. We studied the mechanism of protection induced by MSP1-15, and found that interferon (IFN)-gamma had a major role in protection in all adjuvant systems we examined. Mice that produced low amounts of MSP1-15 stimulated IFN-gamma and could not control parasite infection. The antibody against MSP1-15 did not play a major role in protection in this system. After parasite infection, immunoglobulin G2a antibodies, which had been produced by IFN-gamma stimulation, were induced and subsequently played an important role in eradicating parasites. Thus, both cellular and humoral immune responses were essential for protection from malaria disease. These data revealed that BCG is a powerful adjuvant to induce such a protective immune response against malaria parasites.

Citing Articles

Engineering a dual vaccine against COVID-19 and tuberculosis.

Guthrie C, Tan X, Meeker A, Self A, Liu L, Cheng Y Front Cell Infect Microbiol. 2023; 13:1273019.

PMID: 37965265 PMC: 10641007. DOI: 10.3389/fcimb.2023.1273019.

The BCG Vaccine for COVID-19: First Verdict and Future Directions.

Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, Nistal-Villan E, Ochando J Front Immunol. 2021; 12:632478.

PMID: 33763077 PMC: 7982405. DOI: 10.3389/fimmu.2021.632478.

BCG as a Case Study for Precision Vaccine Development: Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny.

Angelidou A, Diray-Arce J, Conti M, Smolen K, van Haren S, Dowling D Front Microbiol. 2020; 11:332.

PMID: 32218774 PMC: 7078104. DOI: 10.3389/fmicb.2020.00332.

Potential of recombinant Mycobacterium paragordonae expressing HIV-1 Gag as a prime vaccine for HIV-1 infection.

Kim B, Kim B, Kook Y, Kim B Sci Rep. 2019; 9(1):15515.

PMID: 31664100 PMC: 6820866. DOI: 10.1038/s41598-019-51875-6.

Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.

Kim B, Kim B, Kook Y, Kim B Front Immunol. 2018; 9:643.

PMID: 29636755 PMC: 5880907. DOI: 10.3389/fimmu.2018.00643.

References

Holder A, Freeman R, Newbold C . Serological cross-reaction between high molecular weight proteins synthesized in blood schizonts of Plasmodium yoelii, Plasmodium chabaudi and Plasmodium falciparum. Mol Biochem Parasitol. 1983; 9(3):191-6. DOI: 10.1016/0166-6851(83)90096-8. View

Blackman M, Ling I, Nicholls S, Holder A . Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol. 1991; 49(1):29-33. DOI: 10.1016/0166-6851(91)90127-r. View

MILLER L, Roberts T, Shahabuddin M, McCutchan T . Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol. 1993; 59(1):1-14. DOI: 10.1016/0166-6851(93)90002-f. View

Blackman M, Shai S, Holder A . Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med. 1994; 180(1):389-93. PMC: 2191569. DOI: 10.1084/jem.180.1.389. View

Murphy J . Host defenses in murine malaria: nonspecific resistance to Plasmodium berghei generated in response to Mycobacterium bovis infection or Corynebacterium parvum stimulation. Infect Immun. 1981; 33(1):199-211. PMC: 350678. DOI: 10.1128/iai.33.1.199-211.1981. View

Chang S, GIBSON H, Barr P, Hui G . A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol. 1992; 149(2):548-55. View

Daly T, Long C . Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol. 1995; 155(1):236-43. View

del Portillo H, Gysin J, Mattei D, KHOURI E, Udagama P, Mendis K . Plasmodium vivax: cloning and expression of a major blood-stage surface antigen. Exp Parasitol. 1988; 67(2):346-53. DOI: 10.1016/0014-4894(88)90081-1. View

Winter N, Lagranderie M, Rauzier J, Timm J, Leclerc C, Guy B . Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene. 1991; 109(1):47-54. DOI: 10.1016/0378-1119(91)90587-2. View

10.

Hirunpetcharat C, Tian J, Kaslow D, van Rooijen N, Kumar S, Berzofsky J . Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with.... J Immunol. 1997; 159(7):3400-11. View

11.

Matsuo K, Yamaguchi R, Yamazaki A, Tasaka H, Terasaka K, Yamada T . Cloning and expression of the gene for the cross-reactive alpha antigen of Mycobacterium kansasii. Infect Immun. 1990; 58(2):550-6. PMC: 258492. DOI: 10.1128/iai.58.2.550-556.1990. View

12.

Burns Jr J, Majarian W, Young J, Daly T, Long C . A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii. J Immunol. 1989; 143(8):2670-6. View

13.

Clark I, Allison A, Cox F . Protection of mice against Babesia and Plasmodium with BCG. Nature. 1976; 259(5541):309-11. DOI: 10.1038/259309a0. View

14.

Nussenzweig R, Long C . Malaria vaccines: multiple targets. Science. 1994; 265(5177):1381-3. DOI: 10.1126/science.8073276. View

15.

Ding A, Nathan C, Stuehr D . Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol. 1988; 141(7):2407-12. View

16.

von der Weid T, Honarvar N, Langhorne J . Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J Immunol. 1996; 156(7):2510-6. View

17.

Hall R, Hyde J, Goman M, Simmons D, Hope I, Mackay M . Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria. Nature. 1984; 311(5984):379-82. DOI: 10.1038/311379a0. View

18.

Rzepczyk C, Hale K, Woodroffe N, Bobogare A, Csurhes P, Ishii A . Humoral immune responses of Solomon Islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin G3 subclass. Infect Immun. 1997; 65(3):1098-100. PMC: 175094. DOI: 10.1128/IAI.65.3.1098-1100.1997. View

19.

Holder A, Freeman R . Biosynthesis and processing of a Plasmodium falciparum schizont antigen recognized by immune serum and a monoclonal antibody. J Exp Med. 1982; 156(5):1528-38. PMC: 2186849. DOI: 10.1084/jem.156.5.1528. View

20.

Langermann S, Palaszynski S, Burlein J, Koenig S, Hanson M, Briles D . Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med. 1994; 180(6):2277-86. PMC: 2191795. DOI: 10.1084/jem.180.6.2277. View